SCHEMBL10243085

SCHEMBL10243085

CCCCNC(=O)c1cncc(-c2ccco2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
POLB P06746 6/20 0.59
KDM4E B2RXH2 6/20 0.59
HPGD P15428 4/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
MEN1 O00255 3/20 0.59
MAPT P10636 3/20 0.59
KMT2A Q03164 3/20 0.59
CTDSP1 Q9GZU7 2/20 0.59
MCL1 Q07820 2/20 0.59
ALOX15 P16050 1/20 0.59
CASP1 P29466 1/20 0.59
BLM P54132 1/20 0.59
CASP7 P55210 1/20 0.59
HSD17B10 Q99714 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 4/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13876851 0.85 HPGD (0.53) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL10242939 0.84 SMN1; SMN2 (0.65) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL10242974 0.82 ALDH1A1 (0.63) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL10243027 0.81 SMN1; SMN2 (0.59) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL10242946 0.80 SMN1; SMN2 (0.58) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL17742756 0.78 KEAP1 (0.47) ALDH1A1HPGDL3MBTL1MAPTKMT2A
SCHEMBL17742688 0.76 MKNK1 (0.51) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL10242978 0.76 KEAP1 (0.58) ALDH1A1POLBKDM4EHPGDL3MBTL1
SCHEMBL17729031 0.75 KEAP1 (0.64) ALDH1A1POLBKDM4EL3MBTL1MEN1
SCHEMBL569406 0.74 LCLAT1 (0.44) ALDH1A1KDM4EHPGDMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885POLB 3348/4885KDM4E 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.